

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet	1	of	4
-------	---	----	---

**Complete if Known**

Application Number	10/670,100
Filing Date	September 24, 2003
First Named Inventor	Dr. Kenneth D. FINE
Group Art Unit	3661
Examiner Name	NGUYEN, Bao Thuy L
Attorney Docket Number	FINE 01936 C1US

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/670,100
		Filing Date	September 24, 2003
		First Named Inventor	Dr. Kenneth D. Fine
		Group Art Unit	3661
		Examiner Name	Nguyen, Bai Thuy L.
		Attorney Docket Number	FINE 01936 C1US
Sheet	2	of	4


OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BTN	AA	PICARELLI, Antonio, et al.; Gluten-Sensitive Disease with Mild Enteropathy; Gastroenterology 1996; 111; pp 608-616.	
	AB	COOPER, B. T., et al.; Gluten-Sensitive Diarrhea Without Evidence of Celiac Disease; Gastroenterology 1980; 79; pp 801-806.	
	AC	MAIURI L., et al.; Definition of the Initial Immunologic Modifications Upon in Vitro Gliadin Challenge in the Small Intestine of Celiac Patients; Gastroenterology 1966; 110; pp 1368-1378.	
	AD	FERGUSON, A., et al.; Clinical and Pathological Spectrum of Coeliac Disease - Active, silent, latent, potential; Gut 1993; 34; pp 150-151.	
	AE	VENTURA, Alessandro, et al.; Duration of Exposure to Gluten and Risk for Autoimmune Disorders in Patients with Celiac Disease; Gastroenterology 1999 Aug; 117(2); pp 297-303.	
	AF	FINE, Kenneth D., et al.; The Genetic and Histopathologic Relationship of Microscopic Colitis and Celiac Sprue or Refractory Sprue; Gastroenterology 1999; 116; A879. (Abstract)	
	AG	FINE, Kenneth D., et al.; High Prevalence of Celiac Sprue-Like HLA-DQ Genes and Enteropathy in Patients with the Microscopic Colitis Syndrome; Am J Gastroenterol 2000; 95; pp 1974-1982	
	AH	FINE, Kenneth D., et al.; The Prevalence and Causes of Chronic Diarrhea in Patients with Celiac Sprue Treated with a Gluten-Free Diet; Gastroenterology 1997; 112; pp 1830-1837.	
	AI	FINE, Kenneth D., et al.; Colonic Histopathology in Untreated Celiac Sprue or Refractory Sprue: Is it Lymphocytic Colitis or Colonic Lymphocytosis?; Human Pathology 1998; 29; pp 1433-1440.	
	AJ	O'Mahony, S., et al.; Dissociation Between Systemic and Mucosal Humoral Immune Responses in Coeliac Disease; Gut; 1991; Jan; 32(1) pp 29-235.	
BTN	AK	DICKEY, W., et al.; Reliance on Serum Endomysial Antibody Testing Underestimates the True Prevalence of Coeliac Disease by One Fifth; Scand J Gastroenterol 2000; Feb(2); 181-183. Review.	

Examiner Signature	/Bao Thuy Nguyen/	Date Considered	09/20/2006
--------------------	-------------------	-----------------	------------

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please place a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/670,100
		Filing Date	September 24, 2003
		First Named Inventor	Dr. Kenneth D. Fine
		Group Art Unit	3661
		Examiner Name	Nguyen, Bai Thuy L.
Sheet 3	of 4	Attorney Docket Number	FINE 01936 C1US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BTN	AL	ROSTAMI, Kamran, et al.; Sensitivity of Antiendomysium and Antigliadin Antibodies in Untreated Celiac Disease; Am J Gastroenterol; 1999; Apr; 94(4); pp 888-894.	
	AM	GREEN, PHR, et al; Detection of Antiendomysial Antibodies in Adult Celiacs Depends on Histologic and Clinical Disease Severity; Gastroenterology; 116; A883; Abstract. 1999	
	AN	PRASAD, Shyam, et al.; Adult Endomysial Antibody-Negative Coeliac Disease and Cigarette Smoking; Eur J Gastroenterol Hepatol; 2001; Jun; 13(6); pp 667-671.	
	AO	DIETERICH, Walburga, et al.; Autoantibodies to Tissue Transglutaminase as Predictors of Celiac Disease; Gastroenterology 1998; 115; pp 1317-1321.	
	AP	SULKANEN, Satu, et al.; Tissue Transglutaminase Autoantibody Enzyme-Linked Immunosorbent Assay in Detecting Celiac Disease; Gastroenterology 1998; 115; pp 1322-1328.	
	AQ	TRONCONE, Ricardo, et al.; Anti-Gliadin Antibodies; J Pediatric Gastroenterol Nutr 1991; 12; pp 150-158.	
	AR	ANDRE F, et al.; IgE in Stools as Indicator of Food Sensitization; Apr; 50(4); 328-333. Allergy 1995.	
	AS	SASAI, K., et al.; Fecal IgE Levels in Infants at 1 Month of Age as Indicator of Atopic Disease; Allergy; 1994; Oct; 49;(49); pp 791-794.	
	AT	KOLMANNSSKOG, S., et al.; Immunoglobulin E in Extracts of Feces from Children; Inter. Archives of Allergy and Applied Immunology; 1984; 74(1); pp 50-54.	
	AU	KOLMANNSSKOG, S., et al.; The Excretion of IgE with Feces from Healthy Individuals and from Others with Allergy and Diseases Affecting the Intestinal Tract; Int. Archives of Allergy and Applied Immunology; 1986; 79(4); pp 357-364.	
BTN	AV	VADEN, Shelly, et al.; Food Hypersensitivity Reactions in Soft Coated Wheaten Terriers with Protein-Losing Enteropathy or Protein-Losing Nephropathy or Both: Gastroscopic Food Sensitivity Testing, Dietary Provocation, and Fecal Immunoglobulin E; J Vet Inter. Med. 2000; Jan-Feb; 14(1); pp 60-67.	

Examiner Signature	/Bao Thuy Nguyen/	Date Considered	09/20/2006
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

### Complete if Known

Application Number	10/670,100
Filing Date	September 24, 2003
First Named Inventor	Dr. Kenneth D. Fine
Group Art Unit	3661
Examiner Name	Nguyen, Bai Thuy L.
Attorney Docket Number	FINE 01936 C1US

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BTN	AW	KOLMANNKOG, S, et al.; Immunoglobulin E in Feces from Children with Allergy. Evidence of Local Production of IgE in the gut; International Archives Allergy Applied Immunology; 1985; 76(2); pp 133-137.	
BTN	AX	HAAS, L., et al.; Increased Concentrations of Fecal Anti-Gliadin IGA Antibodies in Untreated Celiac Disease; Clinical Chemistry; 1993; April; 39(4); pp 696-697.	
BTN	AY	PICARELLI, Antonio et al.; Antiendomysial Antibody Detection in Fecal Supernatants; Gastroenterology 2000; 118; A 370; Vol. 118; No. 4.	
	BG		

Examiner Signature	/Bao Thuy Nguyen/	Date Considered	09/20/2006
-----------------------	-------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.